How does primary debulking surgery compared to neoadjuvant chemotherapy followed by interval debulking surgery affect overall survival in women with advanced ovarian cancer? : A Systematic Review
Keywords:
Ovarian cancer, primary debulking surgery, neoadjuvant chemotherapy, interval debulking surgery, overall survival, cytoreductionAbstract
Introduction: Advanced epithelial ovarian cancer (stage III-IV) remains a leading cause of gynecologic cancer mortality worldwide. The optimal initial treatment approach—primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS)—continues to generate substantial clinical debate despite multiple randomized trials. This systematic review aims to compare overall survival outcomes between PDS and NACT-IDS in women with advanced ovarian cancer.
Methods: A systematic review was conducted following PRISMA guidelines. We screened studies based on predefined criteria: inclusion of women ≥18 years with FIGO stage III-IV epithelial ovarian cancer, direct comparison of PDS versus NACT-IDS, reporting of overall survival outcomes, and study designs including randomized controlled trials, cohort studies, systematic reviews, and meta-analyses. Data extraction encompassed study characteristics, patient selection criteria, treatment details, survival outcomes, surgical outcomes, and subgroup analyses.
Results: Eighty studies were included, comprising five major RCTs (EORTC 55971, CHORUS, SCORPION, JCOG0602, TRUST) and numerous meta-analyses and observational studies. Meta-analyses demonstrated no significant difference in overall survival between PDS and NACT-IDS (HR 0.96, 95% CI 0.86-1.08) [1-3]. Individual RCTs confirmed similar findings: EORTC 55971 (HR 0.98, 90% CI 0.84-1.13) [4], CHORUS (HR 0.87, 95% CI 0.72-1.05) [5], and TRUST (HR 0.89, 95% CI 0.74-1.08) [6]. However, NACT-IDS achieved superior complete cytoreduction rates (RR 2.34, 95% CI 1.48-3.71) [2] with significantly lower perioperative mortality (RR 0.16, 95% CI 0.06-0.46) and major complications (RR 0.22, 95% CI 0.13-0.38) [1]. Observational studies consistently favored PDS, reflecting selection bias [7,8]. Stage-specific analysis revealed NACT-IDS benefited stage IV disease (HR 0.76, 95% CI 0.58-1.00) [9], while PDS showed advantage in stage III with limited metastatic burden [6,8].
Discussion: The apparent contradiction between RCT and observational evidence reflects fundamental differences in patient selection, surgical quality, and study design. Complete cytoreduction at PDS identifies a biologically favorable subset with superior outcomes, whereas achieving complete resection after NACT may indicate chemotherapy responsiveness without equivalent survival benefit. NACT-IDS offers clear perioperative safety advantages, making it preferable for unresectable disease, poor performance status, and extensive stage IV disease. Optimal treatment selection requires accurate preoperative assessment of resectability, patient fitness, and surgical expertise.
Conclusion: PDS and NACT-IDS provide comparable overall survival in advanced ovarian cancer when patients are appropriately selected. PDS remains preferred when complete cytoreduction is achievable by experienced surgeons in fit patients with stage IIIC disease. NACT-IDS is a safe, effective alternative for patients with unresectable disease, poor fitness, or extensive stage IV disease. Future research should focus on validated prediction models incorporating clinical, imaging, and molecular markers to optimize individualized treatment selection.
References
S. Coleridge, A. Bryant, S. Kehoe, J. Morrison (2021) Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD005343.pub6
Alexander A. Tzanis, C. Iavazzo, A. Hadjivasilis, et al (2022) Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis. Oncology Reviews. https://doi.org/10.3389/or.2022.10605
Matteo Secchi, Mauro Signorelli, E. Rulli, et al (2025) Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116116
I. Vergote, C. Tropé, F. Amant, et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa0908806
S. Kehoe, J. Hook, M. Nankivell, et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. https://doi.org/10.1016/S0140-6736(14)62223-6
Sven Mahner, F. Heitz, Sahar Salehi, et al (2025) TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba5500
Y. Lyons, H. Reyes, M. Mcdonald, et al (2019) Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-001124
B. Seagle, S. Graves, A. Strohl, S. Shahabi (2017) Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study. International Journal of Gynecologic Cancer. https://doi.org/10.1097/IGC.0000000000001072
I. Vergote, C. Coens, M. Nankivell, et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(18)30566-7
Mohamed Shawky, Cherry Choudhary, S. Coleridge, et al (2025) Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD005343.pub7
A. Fagotti, M. G. Ferrandina, G. Vizzielli, et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2020-001640
S. Coleridge, A. Bryant, Thomas J Lyons, et al (2019) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD005343.pub4
S. Coleridge, A. Bryant, S. Kehoe, J. Morrison (2021) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005343.pub2
L. Chiva, P. Ordás, Jagannath Mishra, et al (2025) SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2025.101707
A. Tzanis, C. Iavazzo, A. Hadjivasilis, et al (2021) 1125 Neoadjuvant chemotherapy versus primary debulking surgery in FIGO stage III and IV epithelial ovarian, tubal or peritoneal cancer. Ovarian cancer. https://doi.org/10.1136/ijgc-2021-esgo.516
L. Kumar, R. Hariprasad, S. Kumar, et al (2006) Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): A phase III randomized study. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2006.24.18_SUPPL.15000
G. Scambia, F. Legge (2010) Faculty Opinions recommendation of Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. https://doi.org/10.3410/f.6000962.6007065
Longjia Zeng, Chun-Lin Xiang, Y. Gong, et al (2016) Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis. Scientific Reports. https://doi.org/10.1038/srep35914
T. May, Robyn Comeau, P. Sun, et al (2017) A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. International Journal of Gynecologic Cancer. https://doi.org/10.1097/IGC.0000000000000946
Yunyun Xiao, Shuang Xie, Ningning Zhang, et al (2017) Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000485618
B. Rosen, S. Laframboise, S. Ferguson, et al (2014) The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2014.07.004
H. Machida, H. Tokunaga, K. Matsuo, et al (2019) Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2019.11.520
S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, et al (2016) Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD006014.pub7
M. Hegazy, R. Hegazi, Mohamed Elshafei, et al (2005) Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World Journal of Surgical Oncology. https://doi.org/10.1186/1477-7819-3-57
Meng Qin, Ying Jin, Li Ma, et al (2017) The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. OncoTarget. https://doi.org/10.18632/oncotarget.23808
O. Filippova, D. Chi (2018) The Unyielding Fight Against the Premature Death of Patients With Advanced-Stage Ovarian Cancer. Obstetrics and Gynecology. https://doi.org/10.1097/AOG.0000000000002883
A. Makar, C. Tropé, P. Tummers, et al (2016) Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2015-0239
R. Bristow, D. Chi (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology. https://doi.org/10.1016/J.YGYNO.2006.06.025
J. Morrison, K. Haldar, S. Kehoe, T. Lawrie (2012) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD005343.pub3
L. Chiva, F. Lapuente, T. Castellanos, et al (2016) What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer? Annals of Surgical Oncology. https://doi.org/10.1245/s10434-015-5051-9
M. Milam, X. Tao, R. Coleman, et al (2010) Neoadjuvant Chemotherapy Is Associated With Prolonged Primary Treatment Intervals in Patients With Advanced Epithelial Ovarian Cancer. International Journal of Gynecologic Cancer. https://doi.org/10.1097/IGC.0b013e3182013e2f
C. Vermeulen, W. Tadesse, M. Timmermans, et al (2017) Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology. https://doi.org/10.1016/j.ejogrb.2017.10.019
Uzma Chishti, A. Aziz (2015) Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women. JPMA The Journal of the Pakistan Medical Association
A. Reuss, A. du Bois, P. Harter, et al (2019) TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-000682
Lorena Gonzalez Gea, Ingrid Perez Martinez, E. Civeira, et al (2022) 2022-RA-791-ESGO Primary debulking surgery versus neoadjuvant chemotherapy and interval debulking surgery for advanced epithelial ovarian cancer. Ovarian cancer. https://doi.org/10.1136/ijgc-2022-esgo.559
J. Rauh-Hain, N. Rodriguez, W. Growdon, et al (2012) Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-011-2100-x
Jennifer J. Mueller, Qin C Zhou, A. Iasonos, et al (2016) Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2016.01.008
S. Gill, M. McGree, A. Weaver, et al (2017) Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2016.11.021
Ali Mohammad Azmi, Mohammad Sabry Elkady, Ahmad Hassan Abd-Elaziz, et al (2024) Retrospective Study of Survival Outcome of Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer in Ain Shams University Hospitals Patients. The Quarterly journal of medicine. https://doi.org/10.1093/qjmed/hcae070.370
Hong Zheng, Yu-nong Gao (2012) Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. https://doi.org/10.3978/j.issn.1000-9604.2012.09.02
R. Kessous, I. Laskov, J. Abitbol, et al (2017) Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2016.12.017
B. Kobal, M. Noventa, B. Cvjetičanin, et al (2018) Primary Debulking Surgery Versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals. Radiology and Oncology. https://doi.org/10.2478/raon-2018-0030
Mounika Pottala, S. Jajoo (2021) Comparing the Effectiveness of the Treatment with Neoadjuvant Chemotherapy Followed By Interval Debulking and Primary Debulking Followed By Adjuvant Chemotherapy in Advanced Stage Malignant Ovarian Tumors: A Rural Based Study. Journal of Pharmaceutical Research International. https://doi.org/10.9734/JPRI/2021/V33I37B32037
A. Markauskas, O. Mogensen, R. dePont Christensen, P. T. Jensen (2014) Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter? International Journal of Gynecologic Cancer. https://doi.org/10.1097/IGC.0000000000000241
Nashmia Al Mutairi, T. Le (2019) Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery? Journal of Obstetrics and Gynaecology Canada. https://doi.org/10.1016/j.jogc.2018.05.031
G. Siesto, R. Cavina, F. Romano, D. Vitobello (2016) Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis. American Journal of Clinical Oncology. https://doi.org/10.1097/COC.0000000000000262
U. Solmaz, E. Mat, M. Dereli, et al (2015) Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone? Journal of BUON : official journal of the Balkan Union of Oncology
Peter G. Rose, Patil Sujata, Meng Yao, et al (2025) Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2025.104449
F. Fanfani, G. Ferrandina, G. Corrado, et al (2003) IMPACT OF INTERVAL DEBULKING SURGERY ON CLINICAL OUTCOME IN PRIMARY UNRESECTABLE FIGO STAGE IIIC OVARIAN CANCER PATIENTS. International Journal of Gynecologic Cancer. https://doi.org/10.1159/000074644
T. Onda, T. Satoh, G. Ogawa, et al (2020) Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2020.02.020
J. Hou, M. Kelly, Herbert Yu, et al (2007) Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic Oncology. https://doi.org/10.1016/J.YGYNO.2006.11.025
L. Chiva, P. Ordás, N. Martín-Calvo, et al (2024) An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial). International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2024-005354
P. Morice, G. Dubernard, A. Rey, et al (2003) Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons. https://doi.org/10.1016/J.JAMCOLLSURG.2003.06.004
Shashank Shekhar, Pratibha Singh, J. Vishnoi, et al (2023) Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1146_20
J. Sehouli, K. Savvatis, E. Braicu, et al (2010) Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis. International Journal of Gynecologic Cancer. https://doi.org/10.1111/IGC.0b013e3181f15714
E. Stoeckle, Lionnel Bourdarias, F. Guyon, et al (2014) Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-013-3278-x
C. Tropé, M. Elstrand, B. Sandstad, et al (2012) Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? European Journal of Cancer. https://doi.org/10.1016/j.ejca.2012.01.031
V. Tius, C. Taliento, M. Arcieri, et al (2025) Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111355
H. V. van Meurs, P. Tajik, M. Hof, et al (2013) Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2013.06.013
C. Fagö-Olsen, B. Ottesen, H. Kehlet, et al (2014) Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2013.11.035
Y. Lee, Y. S. Chung, J. Y. Lee, et al (2018) Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2018.29.e63
Dai-Yuan Ma, B. Tan, Xianfu Li, et al (2013) A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV. World Journal of Surgical Oncology. https://doi.org/10.1186/1477-7819-11-267
E. Greimel, G. Kristensen, M. van der Burg, et al (2013) Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2013.08.014
Y.-Y. Chen, Y-C Ou, H. Lin (2019) EP818 Primary debulking surgery versus primary neoadjuvant chemotherapy with or without interval debulking surgery for advanced stage ovarian cancer: a single institute study. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-esgo.868
Yan Gao, Yuan Li, Chunyu Zhang, et al (2019) Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-019-0562-9
S. Nagao, J. Tamura, T. Shibutani, et al (2023) Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-023-02329-7
Nina Kovačević, E. Škof, Ines Cilenšek, S. Merlo (2021) Management of advanced staged ovarian cancer in a national cancer center: comparison of the efficacy of primary debulking surgery versus neoadjuvant chemotherapy. https://doi.org/10.2174/1573404817666210106093301
J. Stewart, A. Tone, Haiyan Jiang, et al (2016) The optimal time for surgery in women with serous ovarian cancer. Canadian journal of surgery Journal canadien de chirurgie. https://doi.org/10.1503/cjs.014315
Abhiram Kanneganti, Benedict Jia Da Loh, J. Ng (2025) Comparison of clinical and cost outcomes between primary and interval debulking surgery in ovarian cancer. Singapore medical journal. https://doi.org/10.4103/singaporemedj.SMJ-2024-077
T. Gorodnova, A. Sokolenko, V. Ni, et al (2019) BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2018-000175
A. Tjulandina, A. Rumyantsev, K. Morkhov, et al (2018) RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES OF PRIMARY CYTOREDUCTION AND NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER STAGE IIIC–IV. Malignant tumours. https://doi.org/10.18027/2224-5057-2018-8-3-86-94
D. Vlachos, D. Haidopoulos, N. Thomakos, et al (2019) EP1022 Primary vs interval debulking surgery for advanced epithelial ovarian cancer: survival outcomes from a tertiary greek centre. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-esgo.1066
Dengfeng Wang, Guonan Zhang, C. Peng, et al (2021) Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-021-00801-4
Yanhua Jiang, Wenfeng He, H. Yang, et al (2018) Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Journal of BUON : official journal of the Balkan Union of Oncology
A. Altman, G. Nelson, P. Chu, et al (2012) Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. Journal of Obstetrics and Gynaecology Canada. https://doi.org/10.1016/S1701-2163(16)35272-0
María Inés Nastasi Basile, Franco J. Calderaro Di Ruggiero, Mireya González Blanco (2025) Cáncer epitelial de ovario en estadios IIIC y IV: cirugía citorreductora primaria versus cirugía citorreductora de intervalo. Revista de obstetricia y ginecología de Venezuela. https://doi.org/10.51288/00850306
R. Jiang, Jianqing Zhu, J. W. Kim, et al (2020) Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2020.31.e86
François Kraus, H. El Hajj, M. le Deley, et al (2021) A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers. https://doi.org/10.3390/cancers13194925
Shristee Shrestha Prajapati, Anisha Shrestha, Usha Shrestha, et al (2023) Primary Cytoreductive Surgery versus Neoadjuvant Chemotherapy followed by Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer: A Retrospective Cohort Study. Nepalese journal of cancer. https://doi.org/10.3126/njc.v7i1.60019
N. Bacalbaşa, I. Balescu, S. Dima, et al (2015) Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Research
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Amanda Ezra Natasya Napitupulu, Jenary Immanuel Surbakti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
